Giuseppe Penna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8873005/publications.pdf Version: 2024-02-01



CHISEDDE DENNA

#	Article	IF	CITATIONS
1	Functional characterization and immunomodulatory properties of Lactobacillus helveticus strains isolated from Italian hard cheeses. PLoS ONE, 2021, 16, e0245903.	1.1	9
2	Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell, 2021, 39, 708-724.e11.	7.7	175
3	Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. Cell Reports, 2021, 36, 109312.	2.9	13
4	Identification of a choroid plexus vascular barrier closing during intestinal inflammation. Science, 2021, 374, 439-448.	6.0	115
5	Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1. , 2021, 9, e003224.		12
6	Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nature Microbiology, 2020, 5, 511-524.	5.9	248
7	Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. Journal of Hepatology, 2019, 71, 1216-1228.	1.8	388
8	Genomic diversity and immunomodulatory activity of Lactobacillus plantarum isolated from dairy products. Beneficial Microbes, 2017, 8, 597-604.	1.0	11
9	The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nature Medicine, 2016, 22, 624-631.	15.2	214
10	Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nature Communications, 2016, 7, 11037.	5.8	192
11	The immune system in the control of microbiota homeostasis. Italian Journal of Pediatrics, 2015, 41, .	1.0	0
12	A gut-vascular barrier controls the systemic dissemination of bacteria. Science, 2015, 350, 830-834.	6.0	446
13	Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. Journal of Allergy and Clinical Immunology, 2015, 136, 413-422.	1.5	102
14	BALB/c and C57BL/6 Mice Differ in Polyreactive IgA Abundance, which Impacts the Generation of Antigen-Specific IgA and Microbiota Diversity. Immunity, 2015, 43, 527-540.	6.6	247
15	Oral Tolerance Can Be Established via Gap Junction Transfer of Fed Antigens from CX3CR1+ Macrophages to CD103+ Dendritic Cells. Immunity, 2014, 40, 248-261.	6.6	384
16	Lactobacillus paracasei CBA L74 Metabolic Products and Fermented Milk for Infant Formula Have Anti-Inflammatory Activity on Dendritic Cells In Vitro and Protective Effects against Colitis and an Enteric Pathogen In Vivo. PLoS ONE, 2014, 9, e87615.	1.1	83
17	Abstract 627: Immunogenic cell death as novel immune response mechanism to EGFR-targeted therapy in CRC. Cancer Research, 2014, 74, 627-627.	0.4	1
18	Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. Gut, 2012, 61, 1007-1015.	6.1	268

#	Article	IF	CITATIONS
19	Dendritic Cell Modulation by the Vitamin D System. , 2012, , 103-125.		О
20	Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut, 2011, 60, 463-472.	6.1	612
21	Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Journal of Developmental and Physical Disabilities, 2010, 33, 475-488.	3.6	178
22	Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunology Letters, 2010, 131, 49-58.	1.1	71
23	Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Annals of the New York Academy of Sciences, 2010, 1193, 146-152.	1.8	56
24	Human prostatic urethra expresses vitamin D receptor and responds to vitamin D receptor ligation. Journal of Endocrinological Investigation, 2010, 33, 730-738.	1.8	11
25	Prostate autoimmunity: from experimental models to clinical counterparts. Expert Review of Clinical Immunology, 2009, 5, 577-586.	1.3	26
26	Human Benign Prostatic Hyperplasia Stromal Cells As Inducers and Targets of Chronic Immuno-Mediated Inflammation. Journal of Immunology, 2009, 182, 4056-4064.	0.4	155
27	The vitamin D receptor agonist elocalcitol inhibits ILâ€8â€dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NFâ€kB pathways. Prostate, 2009, 69, 480-493.	1.2	87
28	Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Human Immunology, 2009, 70, 345-352.	1.2	190
29	Induction of Tolerogenic Dendritic Cells by Vitamin D Receptor Agonists. Handbook of Experimental Pharmacology, 2009, , 251-273.	0.9	98
30	Synthesis and Anti-inflammatory Properties of 11±,25-Dihydroxy-16-ene-20-cyclopropyl-24- <i>oxo</i> -vitamin D ₃ , a Hypocalcemic, Stable Metabolite of 11±,25-Dihydroxy-16-ene-20-cyclopropyl-vitamin D ₃ . Journal of Medicinal Chemistry, 2009, 52, 2204-2213.	2.9	36
31	196 Monocyte-Dependent and -Independent Modulatory Effects of Vitamin D3 on X4 and R5 HIV-1 Replication in IL-2 Stimulated PBMC. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, .	0.9	Ο
32	Control of autoimmune diseases by the vitamin D endocrine system. Nature Clinical Practice Rheumatology, 2008, 4, 404-412.	3.2	477
33	Spontaneous and Prostatic Steroid Binding Protein Peptide-Induced Autoimmune Prostatitis in the Nonobese Diabetic Mouse. Journal of Immunology, 2007, 179, 1559-1567.	0.4	52
34	Vitamin D receptor agonists as anti-inflammatory agents. Expert Review of Clinical Immunology, 2007, 3, 477-489.	1.3	16
35	1,25-Dihydroxyvitamin D3 Selectively Modulates Tolerogenic Properties in Myeloid but Not Plasmacytoid Dendritic Cells. Journal of Immunology, 2007, 178, 145-153.	0.4	305
36	Calcitriol derivatives with two different side chains at C-20. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 277-281.	1.2	21

#	Article	IF	CITATIONS
37	Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 689-693.	1.2	74
38	Vitamin D Receptor Agonists in the Treatment of Autoimmune Diseases: Selective Targeting of Myeloid but Not Plasmacytoid Dendritic Cells. Journal of Bone and Mineral Research, 2007, 22, V69-V73.	3.1	32
39	Seminal Plasma Cytokines and Chemokines in Prostate Inflammation: Interleukin 8 as a Predictive Biomarker in Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Benign Prostatic Hyperplasia. European Urology, 2007, 51, 524-533.	0.9	250
40	Animal Models of Spontaneous Autoimmune Disease. Methods in Molecular Biology, 2007, 380, 285-311.	0.4	52
41	Vitamin D Receptor Agonists, Cancer and the Immune System: An Intricate Relationship. Current Topics in Medicinal Chemistry, 2006, 6, 1297-1301.	1.0	31
42	Treatment of Experimental Autoimmune Prostatitis in Nonobese Diabetic Mice by the Vitamin D Receptor Agonist Elocalcitol. Journal of Immunology, 2006, 177, 8504-8511.	0.4	112
43	Leukocyte migration to pancreatic islets: a critical step in the pathogenesis of type 1 diabetes. , 2006, , 167-179.		1
44	Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood, 2005, 106, 3490-3497.	0.6	373
45	Manipulating dendritic cells to induce regulatory T cells. Microbes and Infection, 2005, 7, 1033-1039.	1.0	37
46	Exploiting the potential of regulatory T cells in the control of type 1 diabetes. , 2005, , 95-109.		0
47	Inhibition of Type 1 Diabetes Development by Vitamin D Receptor Agonists. Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents, 2005, 4, 645-651.	0.4	2
48	Human Immunodeficiency Virus Type 1 gp120 and Other Activation Stimuli Are Highly Effective in Triggering Alpha Interferon and CC Chemokine Production in Circulating Plasmacytoid but Not Myeloid Dendritic Cells. Journal of Virology, 2005, 79, 12597-12601.	1.5	46
49	A Vitamin D Analog Down-Regulates Proinflammatory Chemokine Production by Pancreatic Islets Inhibiting T Cell Recruitment and Type 1 Diabetes Development. Journal of Immunology, 2004, 173, 2280-2287.	0.4	170
50	Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Seminars in Immunology, 2004, 16, 127-134.	2.7	181
51	Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90, 437-441.	1.2	173
52	Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. Journal of Cellular Biochemistry, 2003, 88, 227-233.	1.2	208
53	Unique Regulation of CCL18 Production by Maturing Dendritic Cells. Journal of Immunology, 2003, 170, 3843-3849.	0.4	144
54	IL-12 Administration Accelerates Autoimmune Diabetes in Both Wild-Type and IFN-γ-Deficient Nonobese Diabetic Mice, Revealing Pathogenic and Protective Effects of IL-12-Induced IFN-γ. Journal of Immunology, 2003, 170, 5491-5501.	0.4	83

#	Article	IF	CITATIONS
55	Cutting Edge: Differential Chemokine Production by Myeloid and Plasmacytoid Dendritic Cells. Journal of Immunology, 2002, 169, 6673-6676.	0.4	173
56	THIOL ANTIOXIDANTS INHIBIT THE FORMATION OF THE INTERLEUKIN-12 HETERODIMER: A NOVEL MECHANISM FOR THE INHIBITION OF IL-12 PRODUCTION. Cytokine, 2002, 17, 285-293.	1.4	17
57	Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells. Human Immunology, 2002, 63, 1164-1171.	1.2	216
58	Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. Journal of Neuroimmunology, 2002, 130, 10-21.	1.1	112
59	Polymorphisms in the II12b gene affect structure and expression of IL-12 in NOD and other autoimmune-prone mouse strains. Genes and Immunity, 2002, 3, 151-157.	2.2	29
60	Induction of transplantation tolerance by 1,25-dihydroxyvitamin D3. Transplantation Proceedings, 2001, 33, 58-59.	0.3	9
61	Inhibition of costimulatory pathways for T-cell activation by 1,25-dihydroxyvitamin D3. Transplantation Proceedings, 2001, 33, 2083-2084.	0.3	14
62	Cutting Edge: Selective Usage of Chemokine Receptors by Plasmacytoid Dendritic Cells. Journal of Immunology, 2001, 167, 1862-1866.	0.4	297
63	IL-12 Administration Reveals Diabetogenic T Cells in Genetically Resistant I-Eα-Transgenic Nonobese Diabetic Mice: Resistance to Autoimmune Diabetes Is Associated with Binding of Eα-Derived Peptides to the I-Ag7 Molecule. Journal of Immunology, 2001, 167, 4104-4114.	0.4	13
64	Delivery to the Central Nervous System of a Nonreplicative Herpes Simplex Type 1 Vector Engineered with the Interleukin 4 Gene Protects Rhesus Monkeys from Hyperacute Autoimmune Encephalomyelitis. Human Gene Therapy, 2001, 12, 905-920.	1.4	57
65	Intrathecal Delivery of IFN-Î ³ Protects C57BL/6 Mice from Chronic-Progressive Experimental Autoimmune Encephalomyelitis by Increasing Apoptosis of Central Nervous System-Infiltrating Lymphocytes. Journal of Immunology, 2001, 167, 1821-1829.	0.4	182
66	The control of T cell responses by dendritic cell subsets. Current Opinion in Immunology, 2000, 12, 114-121.	2.4	215
67	Early Th1 Response in Unprimed Nonobese Diabetic Mice to the Tyrosine Phosphatase-Like Insulinoma-Associated Protein 2, an Autoantigen in Type 1 Diabetes. Journal of Immunology, 2000, 165, 6748-6755.	0.4	37
68	Functional Maturation of Adult Mouse Resting Microglia into an APC Is Promoted by Granulocyte-Macrophage Colony-Stimulating Factor and Interaction with Th1 Cells. Journal of Immunology, 2000, 164, 1705-1712.	0.4	137
69	1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation. Journal of Immunology, 2000, 164, 2405-2411.	0.4	1,146
70	The involvement of IL-12 in murine experimentally induced autoimmune thyroid disease. European Journal of Immunology, 1999, 29, 1933-1942.	1.6	38
71	Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4+ T cell priming and Th1/Th2 cell restimulation. European Journal of Immunology, 1999, 29, 2705-2714.	1.6	115
72	CD40-CD154 interaction and IFN-gamma are required for IL-12 but not prostaglandin E2 secretion by microglia during antigen presentation to Th1 cells. Journal of Immunology, 1999, 162, 1384-91.	0.4	69

#	Article	IF	CITATIONS
73	A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes. Journal of Immunology, 1999, 162, 6630-40.	0.4	9
74	Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice. Journal of Immunology, 1999, 163, 2960-8.	0.4	60
75	Th1 cells induce and Th2 inhibit antigen-dependent IL-12 secretion by dendritic cells. European Journal of Immunology, 1998, 28, 2003-2016.	1.6	75
76	Maturation Stages of Mouse Dendritic Cells in Growth Factor–dependent Long-Term Cultures. Journal of Experimental Medicine, 1997, 185, 317-328.	4.2	793
77	Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. European Journal of Immunology, 1997, 27, 2330-2339.	1.6	119
78	Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice Journal of Experimental Medicine, 1995, 181, 817-821.	4.2	433
79	Animal Models of Spontaneous Autoimmune Disease: Type 1 Diabetes in the Nonobese Diabetic Mouse. , 0, , 285-312.		0